Xolair (omalizumab) is a prescription drug used to treat certain conditions, such as asthma or food allergies. The drug comes as an injection. It’s usually given once every 2 or 4 weeks.

with allergic asthma, and adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Omlyclo is available as subcutaneous injections in two strengths: 75 mg/0.5 mL and 150 mg/1.0 mL.

TORONTO, December 10, 2024--(BUSINESS WIRE)--Celltrion today announced that Health Canada has approved Omlyclo ™, a biosimilar referencing Xolair ... with allergic asthma, and adults with ...

A medication used to treat asthma can now be used to help people ... The most common side effects of Xolair are injection site reactions and fever, but the FDA noted that the drug has also been ...

Omlyclo™ (CT-P39) is the first and only omalizumab biosimilar referencing Xolair ® approved in Canada to treat multiple allergic diseases including chronic idiopathic urticaria (CIU), allergic asthma, ...

Britain’s National Institute for Health and Clinical Excellence (NICE) has decided to withdraw its recommendation for asthma drug, Xolair, citing that a review of up-to-date clinical trial data ...

Xolair is a bimonthly or monthly injection originally approved in 2003 for asthma, which McGraw has been diagnosed with. But doctors had long suspected that Xolair could do more, and they had ...

is the first and only omalizumab biosimilar referencing Xolair® approved in Canada to treat multiple allergic diseases including chronic idiopathic urticaria (CIU), allergic asthma, and chronic ...

The study offers promising solutions ... First New Treatment for Asthma Attacks in 50 Years Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more ...

Recent advances in the treatment of asthma and chronic obstructive pulmonary disease (COPD) have emerged with the introduction of benralizumab, an injection that has proven to outperform traditional ...

The first new treatment for asthma attacks in 50 years may be a “game-changer”, researchers say. Offering patients an injection is more effective than the current care of steroid tablets and ...

2024--(BUSINESS WIRE)--Celltrion today announced that Health Canada has approved Omlyclo ™, a biosimilar referencing Xolair ®. Omlyclo ™ is approved for the treatment of adults and adolescents with ...